BRPI1012971A2 - proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central - Google Patents

proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central

Info

Publication number
BRPI1012971A2
BRPI1012971A2 BRPI1012971A BRPI1012971A BRPI1012971A2 BR PI1012971 A2 BRPI1012971 A2 BR PI1012971A2 BR PI1012971 A BRPI1012971 A BR PI1012971A BR PI1012971 A BRPI1012971 A BR PI1012971A BR PI1012971 A2 BRPI1012971 A2 BR PI1012971A2
Authority
BR
Brazil
Prior art keywords
gdnf
bdnf
application
nervous system
fusion proteins
Prior art date
Application number
BRPI1012971A
Other languages
English (en)
Portuguese (pt)
Inventor
Boivin Dominique
Castaigne Jean-Paul
Demeule Michel
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of BRPI1012971A2 publication Critical patent/BRPI1012971A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1012971A 2009-06-11 2010-06-11 proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central BRPI1012971A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18624609P 2009-06-11 2009-06-11
PCT/CA2010/000889 WO2010142035A1 (en) 2009-06-11 2010-06-11 Fusion proteins for delivery of gdnf and bdnf to the central nervous system

Publications (1)

Publication Number Publication Date
BRPI1012971A2 true BRPI1012971A2 (pt) 2018-01-16

Family

ID=43308346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012971A BRPI1012971A2 (pt) 2009-06-11 2010-06-11 proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central

Country Status (9)

Country Link
US (1) US20120196803A1 (enExample)
EP (1) EP2440581A4 (enExample)
JP (1) JP2012529272A (enExample)
CN (2) CN102459348A (enExample)
AU (1) AU2010258052A1 (enExample)
BR (1) BRPI1012971A2 (enExample)
CA (1) CA2764777A1 (enExample)
MX (1) MX2011013258A (enExample)
WO (1) WO2010142035A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
JP5436856B2 (ja) 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
AU2017263174A1 (en) 2016-05-13 2018-12-13 Instituto de Medicina Molecular João Lobo Antunes Methods of treating diseases associated with ILC3 cells
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
CN107141354A (zh) * 2017-05-05 2017-09-08 李斯文 一种融合蛋白及光敏剂复合物及其制备方法和应用
KR20210012966A (ko) * 2019-07-24 2021-02-03 주식회사 에스엘바이젠 불사화된 줄기세포주의 제조 방법 및 이의 용도
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー.アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳-脂肪回路を介してilc2および肥満度を制御する神経-間葉単位
CN116270429B (zh) * 2023-02-17 2025-06-10 山东省药学科学院 一种鼻黏膜给药的抗抑郁制剂及其制备方法和应用
CN120077136A (zh) * 2023-09-28 2025-05-30 广州必贝特医药股份有限公司 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101160403B (zh) * 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
EP2789628A3 (en) * 2007-05-29 2015-03-04 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) * 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) * 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns

Also Published As

Publication number Publication date
AU2010258052A1 (en) 2012-01-12
JP2012529272A (ja) 2012-11-22
CN102459348A (zh) 2012-05-16
CA2764777A1 (en) 2010-12-16
CN103819564A (zh) 2014-05-28
EP2440581A4 (en) 2013-03-27
WO2010142035A1 (en) 2010-12-16
EP2440581A1 (en) 2012-04-18
US20120196803A1 (en) 2012-08-02
MX2011013258A (es) 2012-02-28

Similar Documents

Publication Publication Date Title
EP2440581A4 (en) FUSION PROTEINS FOR THE DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM
BRPI1007004A2 (pt) sistema de iluminação, e, aparelho de estereolitografia
BRPI0913526A2 (pt) sistema de aquecimento
EE01079U1 (et) Territooriumi ja selle perimeetri j„lgimise ssteem
BRPI1006922A2 (pt) sistema para descarte de medicação
BRPI0912144A2 (pt) configuração de sistema de infusão
BR112012008074A2 (pt) derivados de piridina e pirazina como moduladores de proteína quinase
BRPI1012304A2 (pt) sistema para auxílio de subida
PT3058875T (pt) Sistema para tratamento cosmético e imagiologia
BRPI0917867A2 (pt) método e sistema para formar estruturas reticuladas de compósito de suporte
ES2864688T8 (es) Sistema de ablación
LT2414015T (lt) Laringoskopas ir sistema
BR112012016186A2 (pt) sistema de recorte para preparar fusão sacroilíaca
BRPI1009247A2 (pt) sistema de comando de aeronave, e, aeronave
BR112012002092A2 (pt) sistema de dessalinização e metodo de dessalinização
BRPI0814521A2 (pt) Sistema de desidratação e método de desidratação
BR112015006428A2 (pt) sistema aperfeiçoados de registro de rolos e estruturas associadas
BR112013012346A2 (pt) sistema de filtração
BR112013010183A2 (pt) sistema e método para soldador com funcionalidade de solicitação de ajuda
BR112012000444A2 (pt) sistema de dessalinização e método de dessalinização
BRPI0919749A2 (pt) método para embalagem de cigarro e sistema de embalagem de cigarro
BR112012031415A2 (pt) método de inercialização e sistema de inercialização
BRPI0911586A2 (pt) sistema e método de broadcast supereconômico
BR112013014751A2 (pt) sistema de manta para esterilização e métodos de uso
BR112013033525A2 (pt) sistema e método de aquecedor flashline

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 17/00 (2006.01), A61K 38/16 (2006.0

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]